Half Year 2023 Poxel SA Earnings Call TranscriptSep 26, 2023$0.6Earnings- Q4 2022 Poxel SA Earnings Call TranscriptMar 23, 2023$2.6Earnings
- Half Year 2022 Poxel SA Earnings Call TranscriptSep 21, 2022$2.6Earnings
- Full Year 2021 Poxel SA Earnings Call TranscriptMar 22, 2022$5.83Earnings
- Half Year 2021 Poxel SA Earnings Call(English) TranscriptSep 23, 2021$6.7Earnings
- Poxel SA New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Corporate Call TranscriptJul 12, 2021
- Full Year 2020 Poxel SA Earnings Call TranscriptMar 25, 2021$8Earnings
- Poxel S.A. - Special Call TranscriptDec 14, 2020
- Poxel S.A. - Special Call TranscriptOct 01, 2020
- Half Year 2020 Poxel SA Earnings Call TranscriptSep 15, 2020$7.8Earnings
- Full Year 2019 Poxel SA Earnings Call TranscriptMar 26, 2020$6.03Earnings
- Poxel SA - Special Call TranscriptDec 20, 2019
- Poxel SA - Special Call TranscriptNov 26, 2019
- Half Year 2019 Poxel SA Earnings Call TranscriptAug 26, 2019$6.98Earnings
- Poxel SA - Special Call TranscriptJun 25, 2019
- Poxel SA - Special Call TranscriptApr 09, 2019
- Full Year 2018 Poxel SA Earnings Call TranscriptMar 21, 2019$9.03 (+10.93%)Earnings
Q4 2022 Poxel SA Earnings Call Transcript
(technical difficulty)
(Operator Instructions) I now hand over to Thomas.
Thank you, Nicolas. Hey, everyone, and good morning, good afternoon. Thank you for joining us today. I'm Thomas Kuhn, the CEO of Poxel. After my introductory comments, highlighting our key achievements of 2022 and early 2023, I will go into the details of today's announcement where we did our debt restructuring and a new equity linked financing. And I will give you an update on the recent trend of TWYMEEG sales, our lead product. I will then review the full year 2022 financial results.
Before leaving the floor to David, our Chief Scientific Officer. David will provide an update on our clinical pipeline and will then conclude and open the call for questions.
Before we begin, this is our forward-looking statement. Forward-looking statements are subject to inherent risks and uncertainties beyond the company's control that could cause the company's actual results or performance to be materially different
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
